Literature DB >> 3416080

Effects of recombinant human erythropoietin on megakaryocytes and on platelet production in the rat.

M V Berridge1, J K Fraser, J M Carter, F K Lin.   

Abstract

The contention that erythropoietin (Epo) affects platelet production was investigated in the rat with recombinant human Epo (rHuEpo). In normal rats, Epo caused a dose-dependent increase in both reticulocyte and platelet numbers, the reticulocyte response preceding that of platelets. Withdrawal of Epo resulted in reticulocytes and platelets returning to control levels. [75Se]-selenomethionine incorporation into platelets was also enhanced in response to Epo. Chronic daily administration of rHuEpo resulted in steady state erythrocyte levels after 12 to 14 days, which were elevated 20% above controls. Attainment of this steady state was associated with both reticulocytes and platelets returning to control levels despite continued administration of Epo, an effect not associated with a change in the half-life of circulating Epo. In polycythemic rats a platelet response was observed before an effect on reticulocytes. Erythropoietin caused a 2.4-fold increase in the frequency of small acetylcholinesterase-positive cells within 24 hours, and increased the mean megakaryocyte diameter within 48 hours. Furthermore, the [3H]-thymidine labeling index of megakaryocytes from rats treated for 24 hours with rHuEpo was increased for all stages of megakaryocyte maturation. These results support the proposal of an effect of Epo on rat megakaryocytes causing increased platelet production.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3416080

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  18 in total

1.  Geminin deletion from hematopoietic cells causes anemia and thrombocytosis in mice.

Authors:  Kathryn M Shinnick; Elizabeth A Eklund; Thomas J McGarry
Journal:  J Clin Invest       Date:  2010-12       Impact factor: 14.808

2.  Stimulation of thrombopoiesis in mice by human recombinant interleukin 6.

Authors:  R J Hill; M K Warren; J Levin
Journal:  J Clin Invest       Date:  1990-04       Impact factor: 14.808

Review 3.  [Thrombocytopathy and blood complications in uremia].

Authors:  Walter H Hörl
Journal:  Wien Klin Wochenschr       Date:  2006-04       Impact factor: 1.704

4.  A multicenter randomized, double-blind, placebo-controlled late-phase II/III study of recombinant human interleukin 11 in acute myelogenous leukemia.

Authors:  Kensuke Usuki; Akio Urabe; Yasuo Ikeda; Yasuo Ohashi; Hideaki Mizoguchi; Fumimaro Takaku
Journal:  Int J Hematol       Date:  2007-01       Impact factor: 2.490

5.  The effect of thrombopoietin on erythroid progenitors in Diamond-Blackfan anemia.

Authors:  Hirohide Kawasaki; Takahide Nakano; Urara Kohdera; Yohnosuke Kobayashi
Journal:  Int J Hematol       Date:  2002-05       Impact factor: 2.490

Review 6.  Erythropoietin.

Authors:  H Franklin Bunn
Journal:  Cold Spring Harb Perspect Med       Date:  2013-03-01       Impact factor: 6.915

7.  Erythropoiesis in mouse omental milky spots induced by erythropoietin: light and electron microscopic study.

Authors:  K Hirai; N Takemori; M Namiki
Journal:  Int J Exp Pathol       Date:  1994-10       Impact factor: 1.925

8.  Recombinant human erythropoietin in the treatment of infants with anaemia of prematurity.

Authors:  D S Halpérin; M Félix; P Wacker; G Lacourt; J F Babel; M Wyss
Journal:  Eur J Pediatr       Date:  1992-09       Impact factor: 3.183

9.  Preoperative hemoglobin and platelet count and poor prognostic factors in patients with endometrial carcinoma.

Authors:  Jale Metindir; Gülay Bilir Dilek
Journal:  J Cancer Res Clin Oncol       Date:  2008-06-10       Impact factor: 4.553

Review 10.  Epoetin (recombinant human erythropoietin). A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in anaemia and the stimulation of erythropoiesis.

Authors:  D Faulds; E M Sorkin
Journal:  Drugs       Date:  1989-12       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.